Prime Medicine (PRME) Total Non-Current Liabilities (2023 - 2026)

Prime Medicine (PRME) has 4 years of Total Non-Current Liabilities data on file, last reported at $200.0 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 4.4% year-over-year to $200.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200.0 million (down 4.4% YoY) and the FY2025 annual result came in at $203.9 million, up 47.34% from the prior year.
• Total Non-Current Liabilities eased to $200.0 million in Q1 2026, from $203.9 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $209.2 million in Q1 2025 to a low of $57.1 million in Q2 2024.
• A 4-year average of $148.0 million and a median of $169.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2025 — Total Non-Current Liabilities surged 260.93% — and 2026, when it fell 4.4%.
• Tracing PRME's Total Non-Current Liabilities over 4 years: stood at $60.8 million in 2023, then surged by 127.64% to $138.4 million in 2024, then surged by 47.34% to $203.9 million in 2025, then declined by 1.88% to $200.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $200.0 million (Q1 2026), $203.9 million (Q4 2025), and $205.2 million (Q3 2025), per Business Quant data.